BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2020;11:2040620720979813. [PMID: 33403093 DOI: 10.1177/2040620720979813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Flick AC, Leverett CA, Ding HX, McInturff EL, Fink SJ, Mahapatra S, Carney DW, Lindsey EA, DeForest JC, France SP, Berritt S, Bigi-Botterill SV, Gibson TS, Watson RB, Liu Y, O'Donnell CJ. Synthetic Approaches to the New Drugs Approved During 2020. J Med Chem 2022. [PMID: 35833579 DOI: 10.1021/acs.jmedchem.2c00710] [Reference Citation Analysis]
2 Costa BA, Mouhieddine TH, Richter J. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Target Oncol 2022. [PMID: 35771402 DOI: 10.1007/s11523-022-00897-8] [Reference Citation Analysis]
3 Chia CSB. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads. ChemMedChem 2022;:e202200032. [PMID: 35384350 DOI: 10.1002/cmdc.202200032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology 2022;27:343-52. [PMID: 35287555 DOI: 10.1080/16078454.2022.2045724] [Reference Citation Analysis]
5 Cappello E, Nieri P. From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial. Life (Basel) 2021;11:1390. [PMID: 34947921 DOI: 10.3390/life11121390] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
6 Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol 2021;14:159. [PMID: 34602074 DOI: 10.1186/s13045-021-01172-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Offidani M, Corvatta L, Morè S, Olivieri A. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther 2021;15:2401-15. [PMID: 34103900 DOI: 10.2147/DDDT.S267404] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
8 Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, Khan A. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma. Front Oncol 2021;11:678634. [PMID: 34046363 DOI: 10.3389/fonc.2021.678634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Goldschmidt H. [Multiple myeloma-soon curable?]. Internist (Berl) 2021;62:562-70. [PMID: 33783581 DOI: 10.1007/s00108-021-01010-3] [Reference Citation Analysis]